49 results on '"Akgün, Eyup"'
Search Results
2. The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioids
3. Synthesis, characterization, X-ray structure and photoluminescence properties of two Ce(III) complexes derived from pentadentate ligands
4. Combination of a δ-opioid Receptor Agonist and Loperamide Produces Peripherally-mediated Analgesic Synergy in Mice
5. Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice
6. A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance
7. Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception
8. MMG22 Potently Blocks Hyperalgesia in Cisplatin-Treated Mice
9. Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model
10. FBNTI, a DOR-Selective Antagonist That Allosterically Activates MOR within a MOR–DOR Heteromer
11. Targeting MOR-mGluR5 heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5
12. The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward
13. FBNTI, a DOR-Selective Antagonist That Allosterically Activates MOR within a MOR–DOR Heteromer
14. Combined Glia Inhibition and Opioid Receptor Agonism Afford Highly Potent Analgesics without Tolerance
15. Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease
16. Heteromer Induction: An Approach to Unique Pharmacology?
17. Combined Glia Inhibition and Opioid Receptor Agonism Afford Highly Potent Analgesics without Tolerance.
18. Targeting Putative Mu Opioid/Chemokine Receptor Type 5 Heteromers Potently Attenuates Nociception in a Murine Model of Sickle Cell Disease
19. Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5)
20. Darstellung und Struktur von Pyrazolyl-Kationen mit Polymethin- und Methan-Gerüst
21. Silylenolether-Funktionalisierung, 3. Mitt. Regioselektive Acylierung von Trimethylsilylenolethern mit 2-Alkoxy-1,3-dioxolanen — Synthese von α- und γ-geschützten Dicarbonylverbindungen
22. Zur Reaktion von Phenazon und lithiiertem Phenazon mit Aryl-Carbonyl-Derivaten
23. A novel Schiff base: Synthesis, structural characterisation and comparative sensor studies for metal ion detections
24. Bivalent Ligands That Target μ Opioid (MOP) and Cannabinoid1 (CB1) Receptors Are Potent Analgesics Devoid of Tolerance
25. Molecular Basis for Binding and Subtype Selectivity of 1,4-Benzodiazepine Antagonist Ligands of the Cholecystokinin Receptor
26. MDAN-21: A Bivalent Opioid Ligand Containing mu-Agonist and Delta-Antagonist Pharmacophores and Its Effects in Rhesus Monkeys
27. Modulation of Cell Surface Expression of Nonactivated Cholecystokinin Receptors Using Bivalent Ligand-Induced Internalization
28. Internalization of Two Distinct Receptors in Response to Occupation with a Bivalent Ligand Incorporating a Single Stimulus for Internalization
29. Synthesis and in Vitro Characterization of Radioiodinatable Benzodiazepines Selective for Type 1 and Type 2 Cholecystokinin Receptors
30. Induced Association of μ Opioid (MOP) and Type 2 Cholecystokinin (CCK2) Receptors by Novel Bivalent Ligands
31. Synthesis and characterization of Schiff base metal complexes: their antimicrobial, genotoxicity and electrochemical properties
32. Synthesis and 124I‐labeling of m‐iodophenylpyrrolomorphinan as a potential PET imaging agent for delta opioid (DOP) receptors
33. N1'-(p-[18F]Fluorobenzyl)naltrindole (p-[18F]BNTI) as a potential PET imaging agent for DOP receptors
34. Synthesis of 123I-and labelled 5-iodo-6-nitroquipazine
35. Binding Potency of 6-Nitroquipazine Analogues for the 5-Hydroxytryptamine Reuptake Complex
36. Rapid reduction of sulfones to sulfides using LiAlH4–TiCl4
37. BivalentLigands That Target μ Opioid (MOP)and Cannabinoid1 (CB1) Receptors Are Potent AnalgesicsDevoid of Tolerance.
38. Synthesis and 124I-labeling of m-iodophenylpyrrolomorphinan as a potential PET imaging agent for delta opioid (DOP) receptors.
39. N1'-( p-[18F]Fluorobenzyl)naltrindole ( p-[18F]BNTI) as a potential PET imaging agent for DOP receptors.
40. Reaction of electron rich heterocycles with electrophiles. Formylation of indolesviathiomethylation
41. Tri- und Tetra-aryl (bzw.-hetaryl)-methane als Pharmaka - Chemie, Struktur und Wirkungsprinzipien -.
42. Synthesis of 123I-and labelled 5-iodo-6-nitroquipazine.
43. A novel synthesis of 2-vinylindoles and their utilization in the diels-alder reaction for the formation of new [ c] annellated carbazole derivatives.
44. Zur Konstitution und Konformation von arylsubstituierten (Pyrazolinonyl)(hydroxypyrazolylium)methan-perchloraten.
45. Zur Struktur von (Pyrazolinonyl)-(hydroxypyrazolylium)methanperchloraten NMR-, IR-spektroskopische Studien und Kristallstruktur / The Structure of (Pyrazohnonyl)-(hydroxypyrazolyhum)methaneperchlorates NMR, IR Spectroscopic Studies and Crystal Structure
46. Eine einfache Synthese von α,β-ungesättigten γ-geschützten 1,5-Dicarbonyl-Verbindungen
47. Zum Reaktionsverlauf der Farbreaktion von Phenazon mit Xanthydrol
48. Targeting MOR-mGluR 5 heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5.
49. Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.